Clinical Trial

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a dose-escalation to determine the MTD and/or RPII for combinations of ibrutinib (PCI-32765) plus lenalidomide/rituximab in patients with relapsed/refractory mantle cell lymphoma.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2015-05-13; most recent amendment 2026-03-20.
Status change: Recruiting → Active, Not Recruiting 2020-04-13
Trial Details
NCT Number NCT02446236
Lead Sponsor Hackensack Meridian Health
Conditions Mantle Cell Lymphoma
Enrollment 27 participants
Start Date 2015-06-18
Primary Completion 2017-01-03 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-03-24